FDA clears at-home start dose for Alzheimer's drug Leqembi

<![CDATA[FDA Approves At-Home Starting Dose of Lecanemab for Treatment of Alzheimer Disease]]>

FDA approves at-home starter dose of Eisai-Biogen Alzheimer’s drug

(Refiles to add media packaging code, USA-HEALTH/ALZHEIMERS; no change to text or headline) July 13 (Reuters) - The U.S. FDA on Monday appro

FDA Approves LEQEMBI IQLIK® (lecanemab-irmb) Subcutaneous Injection as an Initiation Dose for Early Alzheimer’s Disease

LEQEMBI IQLIK is a first-of-its-kind anti-amyloid treatment worldwide, offering at-home dosing for initiation and maintenance (approved in t

FDA Approves Leqembi: First Drug to Slow Alzheimer's Disease Progression

With the FDA giving the green light to Leqembi, there is renewed hope to millions, promising a potential game-changer in the fight against t

Biogen, Eisai win FDA nod for starter dose of subcutaneous Leqembi

Leqembi Iqlik can now be given at home throughout the entire course of treatment, setting it apart from Eli Lilly’s Kisunla, the only other

LEQEMBI® Subcutaneous Autoinjector Clinical Data Supports Similar Efficacy and Safety to IV Formulation in Early Alzheimer’s Disease Presented at the Alzheimer’s Association International Conference® (AAIC®) 2026

New clinical and real-world data support a subcutaneous treatment pathway from initiation through maintenance treatment, offering dosing con